July 29, 2016

Second Quarter 2016 Financial Results

Double-digit revenue and adjusted EPS growth for the 6th consecutive quarter
Sign Up for Alerts Print
Our robust portfolio drove double-digit revenue and adjusted earnings growth in Q2. Our strategic acquisition of Stemcentrx, in addition to regulatory approvals further expanded our presence in oncology and neuroscience. Read the full press release.